IL127351A0 - Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV - Google Patents

Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV

Info

Publication number
IL127351A0
IL127351A0 IL12735197A IL12735197A IL127351A0 IL 127351 A0 IL127351 A0 IL 127351A0 IL 12735197 A IL12735197 A IL 12735197A IL 12735197 A IL12735197 A IL 12735197A IL 127351 A0 IL127351 A0 IL 127351A0
Authority
IL
Israel
Prior art keywords
ftc
zidovudine
hiv
combinations
treatment
Prior art date
Application number
IL12735197A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614022.3A external-priority patent/GB9614022D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL127351A0 publication Critical patent/IL127351A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
IL12735197A 1996-06-25 1997-06-23 Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV IL127351A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2054396P 1996-06-25 1996-06-25
US2102796P 1996-07-02 1996-07-02
GBGB9614022.3A GB9614022D0 (en) 1996-07-04 1996-07-04 Antiviral therapeutic combinations
PCT/EP1997/003247 WO1997049411A1 (en) 1996-06-25 1997-06-23 Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv

Publications (1)

Publication Number Publication Date
IL127351A0 true IL127351A0 (en) 1999-10-28

Family

ID=27268358

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12735197A IL127351A0 (en) 1996-06-25 1997-06-23 Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV

Country Status (26)

Country Link
US (1) US6544961B1 (cs)
EP (1) EP0938321B1 (cs)
JP (1) JP2000515852A (cs)
KR (1) KR20000022226A (cs)
CN (1) CN1228026A (cs)
AP (1) AP9801419A0 (cs)
AT (1) ATE257708T1 (cs)
AU (1) AU727983B2 (cs)
BR (1) BR9709939A (cs)
CA (1) CA2258956A1 (cs)
CO (1) CO4900074A1 (cs)
CZ (1) CZ429498A3 (cs)
DE (1) DE69727240T2 (cs)
EA (1) EA001517B1 (cs)
ES (1) ES2213217T3 (cs)
HU (1) HUP9903249A3 (cs)
ID (1) ID19490A (cs)
IL (1) IL127351A0 (cs)
IS (1) IS4915A (cs)
NO (1) NO986034L (cs)
NZ (1) NZ333099A (cs)
PL (1) PL330747A1 (cs)
TR (1) TR199802704T2 (cs)
TW (1) TW469132B (cs)
WO (1) WO1997049411A1 (cs)
YU (1) YU58398A (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
JP2008528572A (ja) * 2005-02-01 2008-07-31 トロイカ ファーマスーティカルズ リミテッド ジクロフェナクおよびその薬学的に許容しうる塩の注射可能な調製品
ES2279707B1 (es) * 2005-11-10 2008-06-01 Combino Pharm, S.L. Formulaciones orales que comprenden 3'-azidonucleosidos.
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
EP2178893A4 (en) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc ORAL FORMULATIONS FOR PICOPLATIN
EP2249827A4 (en) * 2008-02-08 2012-05-30 Poniard Pharmaceuticals Inc USE OF PICOPLATIN AND CETUXIMAB IN THE TREATMENT OF COLORECTAL CANCER
ME03058B (me) 2010-01-27 2019-01-20 Viiv Healthcare Co Antivirusna terapija

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IL100502A (en) 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
DK0513917T4 (da) 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
WO1994004492A1 (en) 1992-08-25 1994-03-03 G.D. Searle & Co. Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
GB9503850D0 (en) 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5646180A (en) * 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
TW536403B (en) 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy

Also Published As

Publication number Publication date
AP9801419A0 (en) 1998-12-31
YU58398A (en) 1999-11-22
WO1997049411A1 (en) 1997-12-31
DE69727240T2 (de) 2004-11-25
DE69727240D1 (de) 2004-02-19
IS4915A (is) 1998-11-30
CA2258956A1 (en) 1997-12-31
NZ333099A (en) 2000-06-23
PL330747A1 (en) 1999-05-24
CO4900074A1 (es) 2000-03-27
NO986034L (no) 1999-02-23
NO986034D0 (no) 1998-12-22
TW469132B (en) 2001-12-21
US6544961B1 (en) 2003-04-08
HUP9903249A3 (en) 2001-04-28
CN1228026A (zh) 1999-09-08
AU3262797A (en) 1998-01-14
HUP9903249A2 (hu) 2000-10-28
EA001517B1 (ru) 2001-04-23
EP0938321A1 (en) 1999-09-01
BR9709939A (pt) 1999-08-10
EA199801045A1 (ru) 1999-08-26
JP2000515852A (ja) 2000-11-28
EP0938321B1 (en) 2004-01-14
CZ429498A3 (cs) 1999-06-16
ID19490A (id) 1998-07-16
ATE257708T1 (de) 2004-01-15
AU727983B2 (en) 2001-01-04
ES2213217T3 (es) 2004-08-16
TR199802704T2 (xx) 1999-03-22
KR20000022226A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
AP9701089A0 (en) Synergistic combinations of zidovudine 159U89 and 3TC or FTC
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
IL127351A0 (en) Combinations comprising VX478 zidovudine FTC and/or 3TC for use in the treatment of HIV
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
AU2418499A (en) Org-5222 in the treatment of depression
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
EP0437026A3 (en) Use of tandospirone in the treatment of depression
ZA959904B (en) Iminooxymethyleneanilides thei preparation and their use
IL127350A0 (en) Combinations comprising VX478 zidovudine and/or 1592U89 for use in the treatment of HIV
GB2318069B (en) Improvements in or relating to the manufacture of foams and their uses
AU2115197A (en) Compositions and methods useful in the detection and/or treatment of cancerous conditions
AU3061199A (en) Skin treatment compositions and the use thereof
HK1019045A (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
EP1032266A4 (en) USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS
IL109356A0 (en) N-substituted-2-azetidinones and their use in the preparation of n-unsubstituted-2-azetidinones
IL127040A0 (en) Use of substituted azaspirane in the treatment of asthma
HK1017258A (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
LV10385B (en) Use of quinons in the treatment of cancer or aids
AU5408099A (en) Electrically treated composition and use thereof
GB9601347D0 (en) Improvements in or relating to games and the like
GB9600933D0 (en) Improvements in or relating to games and the like
HUP0104267A3 (en) 1,4-diaryl-2-fluoro-1-buten-3-ol compounds and their use in the preparation of 1,4-diaryl-2-fluoro-1,3-butadiane and 1,4-diaryl-2-fluoro-2-butene compounds
HK1020528A (en) Use ofsubstituted azaspirane in the treatment of asthma
SI1011649T1 (en) Use of endipalene in the treatment of psoriasis
GB9419549D0 (en) Polypeptides and their use in the treatment of auto-immune disease